Protocol List

The Protocol List provides a listing of NCI clinical trials supported by the CTSU and generally open to cross-organizational participation. The trials on the list are either active or temporarily closed. Trial accrual is listed with the actual accrual over the total planned accrual and is updated multiple times a day. The screening accrual column lists NA (Not Applicable) for studies that do not have a screening step. The list may be filtered using the filters available on the page or sorted by any topic in the header row by clicking on a column header; click a second time to reverse the sort.

Phase:

*Some accruals have occurred outside of the CTSU systems and are collected manually, thus the total accrual number may not be accurate.

#Protocol
Number
Lead
Organization
NIH
Program
DiseaseStatusProtocol TitlePhaseActual/Planned Intervention AccrualScreening
Accrual
Step
Type(s)
  • First Page
  • Previous Page
  • Page 1 of 6
  • Next Page
  • Last Page
  • Last update: 3:49:45 AM UTC
110146LAO-CT018ETCTNBreast CancerActiveRandomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients with Metastatic Triple Negative Breast CancerII28/70N/AINTERVENTION
210222LAO-CT018ETCTNGastrointestinal Cancer;Solid TumorTemporarily Closed to AccrualA Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid TumorsII24/50N/AINTERVENTION
310292LAO-NCIETCTNSolid TumorActiveDURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid TumorsII76/115N/AINTERVENTION
410330LAO-CT018ETCTNBone CancerTemporarily Closed to AccrualA Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaII19/32N/AINTERVENTION
510504LAO-NCIETCTNSoft Tissue Cancer/SarcomaActiveA Randomized Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)II8/77N/AINTERVENTION
610507LAO-MA036ETCTNMiscellaneous and Metastatic CancerActiveA Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT CarcinomaI/II13/18N/AINTERVENTION
710579LAO-PA015ETCTNGastrointestinal Cancer;Solid TumorActivePhase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid TumorsI4/30N/AINTERVENTION
810603LAO-MA036ETCTNMale Reproductive System CancerActiveA Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate CancerII2/17N/AINTERVENTION
910612LAO-CT018ETCTNMyelomaActiveA Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple MyelomaII0/70N/AINTERVENTION
10A021806ALLIANCENCTNGastrointestinal CancerActiveA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic CancerIII250/352N/AINTERVENTION
11A021901ALLIANCENCTNEndocrine CancerActiveRandomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine TumorsII13/108N/AINTERVENTION
12A041703ALLIANCENCTNLeukemiaActiveA Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory DiseaseII59/64N/AINTERVENTION
13A051902ALLIANCENCTNLymphomaActiveA Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell LymphomasII43/182N/AINTERVENTION
14A071401ALLIANCENCTNCNS Cancer (Primary tumor)ActivePhase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway MutationsII90/124468SCREENING, INTERVENTION
15A091903ALLIANCENCTNSkin CancerActiveA Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal MelanomaII28/99N/AINTERVENTION
16A092105ALLIANCENCTNHead and Neck CancerActiveRandomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and ImmunotherapyII3/50N/AINTERVENTION
17A211801ALLIANCENCORPN/AActiveBRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline MutationIII30/300N/AINTERVENTION
18A212102ALLIANCENCORPMiscellaneous and Metastatic CancerActiveBlinded Reference Set For Multicancer Early Detection Blood TestsOtherN/AN/AOTHER
19ACCL1931COGNCORPMiscellaneous and Metastatic CancerActiveA Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia TherapyIII36/440N/AINTERVENTION
20AOST2032COGNCTNBone CancerTemporarily Closed to AccrualA Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed OsteosarcomaII/III10/528N/AINTERVENTION
21DCP-001DCPNCORPHematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid TumorActiveUse of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)OtherN/AN/AOTHER
22EA1211ECOG-ACRINNCTNBreast CancerActiveInterim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT TrialII34/235N/AINTERVENTION
23EA2174ECOG-ACRINNCTNGastrointestinal CancerTemporarily Closed to AccrualA Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction AdenocarcinomaII/III275/278N/AINTERVENTION
24EA2176ECOG-ACRINNCTNGastrointestinal CancerActiveA Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer PatientsIII178/205N/AINTERVENTION
25EA2192ECOG-ACRINNCTNGastrointestinal CancerActiveAPOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationII59/152N/AINTERVENTION
26EA6141ECOG-ACRINNCTNSkin CancerActiveRandomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV MelanomaII/III476/601N/AINTERVENTION
27EA8134ECOG-ACRINNCTNMale Reproductive System CancerActiveInPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)III91/200N/AINTERVENTION
28EA8192ECOG-ACRINNCTNUrothelial/ Bladder CancerActiveA Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to NephroureterectomyII/III42/249N/AINTERVENTION
29EA8212ECOG-ACRINNCTNUrothelial/ Bladder CancerActiveA Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)III367/870N/AINTERVENTION
30EAA173ECOG-ACRINNCTNMyelomaActiveDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)III168/288N/AINTERVENTION
31EAQ211ECOG-ACRINNCORPLymphomaActiveSocial Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin LymphomaOtherN/AN/AOTHER
32EAY191ECOG-ACRINNCTNLymphoma;Solid TumorActiveMolecular Analysis for Combination Therapy Choice (ComboMATCH)OtherN/A130SCREENING
33EAY191-N5NRGNCTNBone Cancer;CNS Cancer (Primary tumor);Endocrine Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Germ Cell Cancer;Head and Neck Cancer;Kidney Cancer;Lung, Mediastinal, and Pleural Cancer;Male Reproductive System Cancer;Miscellaneous and Metastatic Cancer;Skin Cancer;Soft Tissue Cancer/Sarcoma;Solid Tumor;Urothelial/ Bladder CancerActiveA Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment TrialII0/70N/AINTERVENTION
34NRG-BR008NRGNCTNBreast CancerActiveA Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)III22/1300N/AINTERVENTION
35NRG-GU012NRGNCTNKidney CancerActiveRandomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)II17/240N/AINTERVENTION
36NRG-GY022NRGNCTNSolid TumorActiveAssessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using CarboplatinI270/350N/AINTERVENTION
37PBTC-061PBTCMISCELLANEOUSCNS Cancer (Primary tumor)ActivePhase 2 Trial of G207 + 5 Gy Radiation for Children with High-Grade GliomasII0/35N/AINTERVENTION
38S1914SWOGNCTNLung, Mediastinal, and Pleural CancerActiveA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLCIII348/480N/AINTERVENTION
39S1933SWOGNCTNLung, Mediastinal, and Pleural CancerActiveA Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance StatusII36/47N/AINTERVENTION
40S2012SWOGNCTNEndocrine CancerActiveRandomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)II/III42/189N/AINTERVENTION
41S2013SWOGNCORPN/AActiveImmune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational StudyOtherN/AN/AOTHER
42S2207SWOGNCTNLymphomaActiveRandomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell LymphomaII10/227N/AINTERVENTION
43S2209SWOGNCTNMyelomaActiveA Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent MaintenanceIII19/510N/AINTERVENTION
4410323DCTDNCIBreast Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Leukemia;Lung, Mediastinal, and Pleural Cancer;Male Reproductive System Cancer;Myeloma;Skin CancerActiveCancer Moonshot Biobank Research ProtocolOtherN/AN/AOTHER
4510324LAO-MD017ETCTNFemale Reproductive System CancerActiveA Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)I53/49N/AINTERVENTION
4610327LAO-CA043ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase I Trial of MLN0128 (Sapanisertib) and Telaglenastat (CB-839) HCL in Advanced NSCLC PatientsI19/85N/AINTERVENTION
4710335LAO-CT018ETCTNLeukemia;LymphomaActiveA Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)I10/30N/AINTERVENTION
4810487LAO-MD017ETCTNMale Reproductive System CancerActiveA Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine DifferentiationII4/30N/AINTERVENTION
4910496LAO-CA043ETCTNHead and Neck CancerActiveA Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckII25/52N/AINTERVENTION
5010508LAO-MA036ETCTNLymphomaActiveA Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)I8/27N/AINTERVENTION